Brief: Moonlake Immunotherapeutics Reports Q3 Financial Results, Provides Recent Business Update
14/11/2022 17:48
Nov 14 (Reuters) - MoonLake Immunotherapeutics MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES RECENT BUSINESS UPDATE
* MOONLAKE IMMUNOTHERAPEUTICS - QTRLY LOSS PER SHARE $0.27
* MOONLAKE IMMUNOTHERAPEUTICS - AS OF SEPTEMBER 30, 2022,
MOONLAKE
HELD CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE DEBT
SECURITIES OF $83.5 MILLION
Source text for Eikon: ID:nGNX7c5RqF
Further company coverage: MLTX.O
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial